دورية أكاديمية
أعرض في EDS

Neutrophil and NETosis Modulation in Traumatic Heterotopic Ossification.

التفاصيل البيبلوغرافية
العنوان: Neutrophil and NETosis Modulation in Traumatic Heterotopic Ossification.
المؤلفون: Nunez JH; Department of Surgery, Center for Organogenesis and Trauma, University of Texas, Southwestern, Dallas, TX., Juan C; Department of Surgery, Center for Organogenesis and Trauma, University of Texas, Southwestern, Dallas, TX., Sun Y; Department of Surgery, Center for Organogenesis and Trauma, University of Texas, Southwestern, Dallas, TX., Hong J; Department of Surgery, Center for Organogenesis and Trauma, University of Texas, Southwestern, Dallas, TX., Bancroft AC; Department of Surgery, Center for Organogenesis and Trauma, University of Texas, Southwestern, Dallas, TX., Hwang C; Department of Plastic Surgery, Harvard University, Cambridge, MA., Medrano JM; Department of Surgery, Center for Organogenesis and Trauma, University of Texas, Southwestern, Dallas, TX., Huber AK; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI., Tower RJ; Department of Surgery, Center for Organogenesis and Trauma, University of Texas, Southwestern, Dallas, TX., Levi B; Department of Surgery, Center for Organogenesis and Trauma, University of Texas, Southwestern, Dallas, TX.
المصدر: Annals of surgery [Ann Surg] 2023 Dec 01; Vol. 278 (6), pp. e1289-e1298. Date of Electronic Publication: 2023 Jun 16.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0372354 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-1140 (Electronic) Linking ISSN: 00034932 NLM ISO Abbreviation: Ann Surg Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Philadelphia, PA : Lippincott Williams & Wilkins
مواضيع طبية MeSH: Neutrophils*/metabolism , Extracellular Traps*/metabolism, Animals ; Mice ; Hydroxychloroquine/metabolism ; Immunity, Innate ; DNA/metabolism
مستخلص: Objective: To characterize the role of neutrophil extracellular traps (NETs) in heterotopic ossification (HO) formation and progression and to use mechanical and pharmacological methods to decrease NETosis and mitigate HO formation.
Background: Traumatic HO is the aberrant osteochondral differentiation of mesenchymal progenitor cells after traumatic injury, burns, or surgery. While the innate immune response has been shown to be necessary for HO formation, the specific immune cell phenotype and function remain unknown. Neutrophils, one of the earliest immune cells to respond after HO-inducing injuries, can extrude DNA, forming highly inflammatory NETs. We hypothesized that neutrophils and NETs would be diagnostic biomarkers and therapeutic targets for the detection and mitigation of HO.
Methods: C57BL6J mice underwent burn/tenotomy (a well-established mouse model of HO) or a non-HO-forming sham injury. These mice were either (1) ambulated ad libitum, (2) ambulated ad libitum with daily intraperitoneal hydroxychloroquine, ODN-2088 (both known to affect NETosis pathways), or control injections, or (3) had the injured hind limb immobilized. Single-cell analysis was performed to analyze neutrophils, NETosis, and downstream signaling after the HO-forming injury. Immunofluorescence microscopy was used to visualize NETosis at the HO site and neutrophils were identified using flow cytometry. Serum and cell lysates from HO sites were analyzed using enzyme-linked immunosorbent assay for myeloperoxidase-DNA and ELA2-DNA complexes to identify NETosis. Micro-computerized tomography was performed on all groups to analyze the HO volume.
Results: Molecular and transcriptional analyses revealed the presence of NETs within the HO injury site, which peaked in the early phases after injury. These NETs were highly restricted to the HO site, with gene signatures derived from both in vitro NET induction and clinical neutrophil characterizations showing a high degree of NET "priming" at the site of injury, but not in neutrophils in the blood or bone marrow. Cell-cell communication analyses revealed that this localized NET formation coincided with high levels of toll-like receptor signaling specific to neutrophils at the injury site. Reducing the overall neutrophil abundance within the injury site, either pharmacologically through treatment with hydroxychloroquine, the toll-like receptor 9 inhibitor OPN-2088, or mechanical treatment with limb offloading, results in the mitigation of HO formation.
Conclusions: These data provide a further understanding of the ability of neutrophils to form NETs at the injury site, clarify the role of neutrophils in HO, and identify potential diagnostic and therapeutic targets for HO mitigation.
Competing Interests: The authors report no conflicts of interest.
(Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
References: J Bone Joint Surg Am. 2001 Dec;83(12):1783-8. (PMID: 11741055)
Adv Drug Deliv Rev. 2008 Apr 29;60(7):795-804. (PMID: 18262306)
PLoS One. 2019 Jul 8;14(7):e0218946. (PMID: 31283757)
Front Immunol. 2019 Oct 24;10:2148. (PMID: 31708911)
FEBS J. 2017 Jun;284(11):1712-1725. (PMID: 28374518)
Sci Rep. 2022 Mar 9;12(1):4136. (PMID: 35264677)
BMC Genom Data. 2021 Nov 14;22(1):49. (PMID: 34775962)
Nat Med. 2014 May;20(5):511-7. (PMID: 24784231)
J Surg Res. 2016 Nov;206(1):53-61. (PMID: 27916375)
Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):888-95. (PMID: 15465207)
J Bone Joint Surg Am. 2007 Mar;89(3):476-86. (PMID: 17332095)
Arterioscler Thromb Vasc Biol. 2018 Aug;38(8):1901-1912. (PMID: 29976772)
Front Immunol. 2020 Dec 18;11:613170. (PMID: 33391283)
J Immunol Res. 2018 Dec 3;2018:8549329. (PMID: 30622982)
J Thromb Haemost. 2016 Mar;14(3):551-8. (PMID: 26712312)
Cell Prolif. 2020 Jan;53(1):e12712. (PMID: 31730279)
Front Mol Biosci. 2022 Feb 18;9:833771. (PMID: 35252353)
J Bone Joint Surg Br. 2006 Dec;88(12):1613-7. (PMID: 17159174)
Clin Exp Immunol. 2023 Mar 24;211(3):239-247. (PMID: 36655514)
Strahlenther Onkol. 2003 Nov;179(11):767-73. (PMID: 14605747)
Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):55-62. (PMID: 8083129)
Front Immunol. 2021 Apr 14;12:645100. (PMID: 33936063)
Nat Commun. 2018 Feb 7;9(1):551. (PMID: 29416028)
J Bone Joint Surg Am. 1992 Feb;74(2):186-200. (PMID: 1541613)
J Bone Joint Surg Br. 1997 Nov;79(6):959-63. (PMID: 9393912)
Stem Cell Reports. 2021 Mar 9;16(3):626-640. (PMID: 33606989)
J Bone Joint Surg Am. 2010 Sep 1;92(11):2032-8. (PMID: 20810853)
J Clin Invest. 2018 Feb 1;128(2):846-860. (PMID: 29355842)
Cochrane Database Syst Rev. 2004;(3):CD001160. (PMID: 15266441)
Trends Immunol. 2003 Jan;24(1):25-9. (PMID: 12495721)
Stem Cells. 2009 Jan;27(1):150-6. (PMID: 18832590)
J Immunol. 2008 Aug 1;181(3):2189-95. (PMID: 18641358)
Ann Rheum Dis. 2019 Feb;78(2):238-248. (PMID: 30563869)
Handb Exp Pharmacol. 2008;(183):51-70. (PMID: 18071654)
Science. 2004 Mar 5;303(5663):1532-5. (PMID: 15001782)
Front Immunol. 2019 Jan 24;10:12. (PMID: 30733715)
Nat Commun. 2021 Aug 16;12(1):4939. (PMID: 34400627)
Front Immunol. 2019 Mar 11;10:423. (PMID: 30915077)
JCI Insight. 2017 Nov 2;2(21):. (PMID: 29093266)
J Vis Exp. 2015 Aug 06;(102):e52880. (PMID: 26274052)
J Clin Invest. 2020 Oct 1;130(10):5444-5460. (PMID: 32673290)
Cytokine. 2011 Apr;54(1):92-9. (PMID: 21292497)
Front Immunol. 2021 Nov 04;12:775267. (PMID: 34804066)
Radiology. 1993 Jul;188(1):257-64. (PMID: 8511308)
Can J Physiol Pharmacol. 2014 Jan;92(1):1-8. (PMID: 24383867)
Circulation. 2018 Aug 28;138(9):898-912. (PMID: 29588315)
J Bone Joint Surg Am. 1981 Feb;63(2):201-8. (PMID: 6780568)
J Bone Joint Surg Am. 2011 Jun 15;93(12):1122-31. (PMID: 21776549)
J Bone Joint Surg Am. 2015 Jul 1;97(13):1101-11. (PMID: 26135077)
Pharmacol Res. 2022 Oct;184:106424. (PMID: 36064077)
Calcif Tissue Int. 2006 Dec;79(6):422-30. (PMID: 17160579)
JCI Insight. 2020 Jun 4;5(11):. (PMID: 32329756)
Sci Rep. 2021 Mar 16;11(1):6063. (PMID: 33727634)
J Vis Exp. 2010 Feb 24;(36):. (PMID: 20182410)
Cell Mol Immunol. 2021 Feb;18(2):374-384. (PMID: 33420357)
Nat Commun. 2020 Feb 5;11(1):722. (PMID: 32024825)
FASEB J. 2020 Dec;34(12):15753-15770. (PMID: 33089917)
J Immunol. 2012 Sep 15;189(6):2689-95. (PMID: 22956760)
Mol Med. 2016 Oct;22:621-631. (PMID: 27453505)
Rheumatol Int. 2020 Nov;40(11):1741-1751. (PMID: 32880032)
Sci Rep. 2021 Dec 14;11(1):24005. (PMID: 34907287)
Radiother Oncol. 1993 Mar;26(3):271-4. (PMID: 8316658)
J Bone Joint Surg Br. 1998 Mar;80(2):259-63. (PMID: 9546456)
معلومات مُعتمدة: R61 AR078072 United States AR NIAMS NIH HHS
المشرفين على المادة: 4QWG6N8QKH (Hydroxychloroquine)
9007-49-2 (DNA)
تواريخ الأحداث: Date Created: 20230616 Date Completed: 20231109 Latest Revision: 20240218
رمز التحديث: 20240218
مُعرف محوري في PubMed: PMC10724380
DOI: 10.1097/SLA.0000000000005940
PMID: 37325925
قاعدة البيانات: MEDLINE
الوصف
تدمد:1528-1140
DOI:10.1097/SLA.0000000000005940